Advertisement
- United States
- /
- Medical Equipment
- /
- NYSE:SYK
How Is Stryker's (NYSE:SYK) CEO Compensated?
Kevin Lobo has been the CEO of Stryker Corporation (NYSE:SYK) since 2012, and this article will examine the executive's compensation with respect to the overall performance of the company. This analysis will also assess whether Stryker pays its CEO appropriately, considering recent earnings growth and total shareholder returns.
See our latest analysis for Stryker
Comparing Stryker Corporation's CEO Compensation With the industry
Our data indicates that Stryker Corporation has a market capitalization of US$76b, and total annual CEO compensation was reported as US$15m for the year to December 2019. That's a modest increase of 7.6% on the prior year. We think total compensation is more important but our data shows that the CEO salary is lower, at US$1.2m.
In comparison with other companies in the industry with market capitalizations over US$8.0b , the reported median total CEO compensation was US$11m. Hence, we can conclude that Kevin Lobo is remunerated higher than the industry median. Moreover, Kevin Lobo also holds US$14m worth of Stryker stock directly under their own name, which reveals to us that they have a significant personal stake in the company.
On an industry level, roughly 21% of total compensation represents salary and 79% is other remuneration. Stryker sets aside a smaller share of compensation for salary, in comparison to the overall industry. If total compensation is slanted towards non-salary benefits, it indicates that CEO pay is linked to company performance.
Stryker Corporation's Growth
Over the past three years, Stryker Corporation has seen its earnings per share (EPS) grow by 8.6% per year. In the last year, its revenue is up 7.8%.
We'd prefer higher revenue growth, but the modest improvement in EPS is good. Considering these factors we'd say performance has been pretty decent, though not amazing. Historical performance can sometimes be a good indicator on what's coming up next but if you want to peer into the company's future you might be interested in this free visualization of analyst forecasts.
Has Stryker Corporation Been A Good Investment?
Boasting a total shareholder return of 42% over three years, Stryker Corporation has done well by shareholders. So they may not be at all concerned if the CEO were to be paid more than is normal for companies around the same size.
In Summary...
As previously discussed, Kevin is compensated more than what is normal for CEOs of companies of similar size, and which belong to the same industry. Importantly though, shareholder returns for the last three years have been excellent. That's why we were hoping earnings growth would match this growth, but sadly that is not the case. We'd ideally want to see higher earnings growth, but CEO compensation seems to be within reason, given high shareholder returns.
CEO compensation is a crucial aspect to keep your eyes on but investors also need to keep their eyes open for other issues related to business performance. That's why we did some digging and identified 3 warning signs for Stryker that investors should think about before committing capital to this stock.
Important note: Stryker is an exciting stock, but we understand investors may be looking for an unencumbered balance sheet and blockbuster returns. You might find something better in this list of interesting companies with high ROE and low debt.
If you’re looking to trade Stryker, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. Their clients from over 200 countries and territories trade stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.
About NYSE:SYK
Stryker
Operates as a medical technology company in the United States and internationally.
Adequate balance sheet average dividend payer.
Similar Companies
Market Insights
Advertisement
Weekly Picks
ST
stuart_roberts on Unicycive Therapeutics ·
Looking to be second time lucky with a game-changing new product
Fair Value:US$21.5370.8% undervalued
49 followersusers have followed this narrative
0 commentsusers have commented on this narrative
9 likesusers have liked this narrative
HE
HegelBayeBagel on PlaySide Studios ·
PlaySide Studios: Market Is Sleeping on a Potential 10M+ Unit Breakout Year, FY26 Could Be the Rerate of the Decade
Fair Value:AU$0.8460.7% undervalued
12 followersusers have followed this narrative
2 commentsusers have commented on this narrative
7 likesusers have liked this narrative
AN
AnimalDoctorKwon on Inotiv ·
Inotiv NAMs Test Center
Fair Value:US$1.278.3% undervalued
19 followersusers have followed this narrative
2 commentsusers have commented on this narrative
6 likesusers have liked this narrative
TH
TheValueDetector on Cognyte Software ·
This isn’t speculation — this is confirmation.A Schedule 13G was filed, not a 13D, meaning this is passive institutional capital, not acti
Fair Value:US$95.6792.9% undervalued
38 followersusers have followed this narrative
2 commentsusers have commented on this narrative
6 likesusers have liked this narrative
Recently Updated Narratives
TO
Tonmoy009 on CSL ·
My view on CSL Limited is positive. It’s a high-quality growth stock with strong barriers to entry through its global plasma network.
Fair Value:AU$140.649.0% overvalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
KA
kabz2342 on Nu Holdings ·
Nu holdings will continue to disrupt the South American banking market
Fair Value:US$64.372.7% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
TE
TexasIronLegend on Tesla ·
The Transition From Automaker To AI Behemoth Is Underway, But Priced In
Fair Value:US$4003.0% overvalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.887.9% undervalued
59 followersusers have followed this narrative
5 commentsusers have commented on this narrative
25 likesusers have liked this narrative
AN
AnalystConsensusTarget on Microsoft ·
Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
Fair Value:US$59633.4% undervalued
1289 followersusers have followed this narrative
2 commentsusers have commented on this narrative
9 likesusers have liked this narrative
TA
Talos on Tesla ·
The "Physical AI" Monopoly – A New Industrial Revolution
Fair Value:US$665.3638.1% undervalued
47 followersusers have followed this narrative
19 commentsusers have commented on this narrative
22 likesusers have liked this narrative
Trending Discussion
TH
TheInvestingFool on PlaySide Studios ·
Looks interesting, I am jumping into the finances now. Your 15% margin seems high for a conservative model, can't just ignore the years they need to invest. You didnt seem to mention that they had to dilute the sharebase by issuing ~40mil shares. raising ~8 mil. should be enough if mouse does OK. If not they will need to raise more to suvive. Losing 20m a year, 14m after there 6m cutbacks. Am I reading it right that they have no debt. have they any history of raising debt? First look it is too dependant on the mouse and GoT games. they do well stock will 2-3x, poorly and it will drop. I am not sure I agree with your work for hire backstop. Unlikely meta horizons will continue with the same size contract going forward. say 10% margins and 15x multiple on 30m. that is 45m, which with the new sharecount is 10c. It is a backstop but maybe not that strong. Mouse fails and devs could start jumping ship and outside contracts could dry up. Hmm on top of all that AI could be disrupting the work for hire model. I think I have mostly talked myself out of it. Although Mouse looks good and does seem like the type of game that could go viral on twitch for a few months. If it does you will likly get a great return 5x plus. crap maybe I am talking myself back in.
1
|0